(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/036096 A3

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2023/071755

(22) International Filing Date:
07 August 2023 (07.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/396,065	08 August 2022 (08.08.2022)	US
63/496,465	17 April 2023 (17.04.2023)	US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: **ALAM, Riazul**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **ALVARADO, Alberto**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **ANDREWS, Forest, Hoyt**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **BABB, Nicholas, Alan**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **BALASUBRAMANIAM, Deepa**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **CHAUVIGNE-HINES, Lacie**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **CORTEZ, Guillermo, S.**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **CROY, Johnny, Eugene**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **DRIVER, David, Albert**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **FELLOWS, Ross, Edward**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **GIRARD, Daniel**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **GONZALEZ VALCARCEL, Isabel, C.**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **KULKARNI, Nalini, Hosahalli**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **LAWRENCE, Scott, Alan**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **LIU, Feng**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **TANI, Hiroaki**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **YORK, Jeremy, S.**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(74) Agent: **GAO, Xiaoguang** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES




Figure 8A

(57) Abstract: Provided herein are proteins comprising one monovalent human TfR binding domain ("human TfR binding proteins"), proteins comprising one monovalent mouse TfR binding domain ("mouse TfR binding proteins"), conjugates comprising such human or mouse TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.

[Continued on next page]

WO 2024/036096 A3

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report:**
25 April 2024 (25.04.2024)